Rejection of Mouse Renal Cell Carcinoma Elicited by Local Secretion of Interleukin‐2
作者： Isao Hara , Hak Hotta , Noriyuki Sato , Hiroshi Eto , Soichi Arakawa
DOI: 10.1111/J.1349-7006.1996.TB00284.X
关键词:
摘要: We introduced the interleukin-2 (IL-2) gene into mouse renal cell carcinoma (RenCa) in order to examine mechanism of tumor rejection. IL-2 gene-transfected RenCa (RenCa/IL-2Hi) exhibited marked retardation growth when implanted a syngeneic host. Growth RenCa/IL-2Hi was also observed athymic nude mice even after depletion natural killer (NK) cells by treatment with anti-asialo GM1 antibody. Histological analysis tumors disclosed non-specific inflammatory changes hosts. Co-injection Bacillus Calmette Guerin considerably enhanced anti-tumor effects. Taken together, these findings strongly suggest that situ production leads rejection through responses without participation T and NK cells. On other hand, had rejected acquired immunity against parental RenCa, suggesting possible memory second tumor.
sci-hub.se 参考文章(20)
Lieping Chen, J. V. Johnston, Yiwen Li, S. A. Newby, K. E. Hellstrom, Protective immunity induced by B7/CD28-costimulated gamma delta T cells to the EL-4 lymphoma in allogenic athymic mice. Journal of Immunology. ,vol. 155, pp. 5705- 5710 ,(1995)
M Nabholz, F Erard, P Corthesy, P Zaech, J W Lowenthal, G Plaetinck, H R MacDonald, Interleukin 2 is both necessary and sufficient for the growth and differentiation of lectin-stimulated cytolytic T lymphocyte precursors. Journal of Immunology. ,vol. 134, pp. 1644- 1652 ,(1985)
W. J. Leonard, D. K. Blanchard, J. Y. Djeu, Sheng Wei, Jin Hong Liu, Activation of tumor necrosis factor-alpha production from human neutrophils by IL-2 via IL-2-R beta. Journal of Immunology. ,vol. 150, pp. 1979- 1987 ,(1993)
Antonella Stoppacciaro, Mirella Giovarelli, Andrea Modesti, Guido Forni, Federica Cavallo, Alessandra Vacca, Alberto Gulino, Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. Journal of Immunology. ,vol. 149, pp. 3627- 3635 ,(1992)
J Connor, R Bannerji, S Saito, W Heston, W Fair, E Gilboa, Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells Journal of Experimental Medicine. ,vol. 177, pp. 1127- 1134 ,(1993) , 10.1084/JEM.177.4.1127
R E Lee, M T Lotze, J M Skibber, E Tucker, R O Bonow, F P Ognibene, J A Carrasquillo, J H Shelhamer, J E Parrillo, S A Rosenberg, Cardiorespiratory effects of immunotherapy with interleukin-2. Journal of Clinical Oncology. ,vol. 7, pp. 7- 20 ,(1989) , 10.1200/JCO.1989.7.1.7
J Miller, R N Germain, Efficient cell surface expression of class II MHC molecules in the absence of associated invariant chain. Journal of Experimental Medicine. ,vol. 164, pp. 1478- 1489 ,(1986) , 10.1084/JEM.164.5.1478
Mario P. Colombo, Guido Forni, Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunology Today. ,vol. 15, pp. 48- 51 ,(1994) , 10.1016/0167-5699(94)90131-7
Isao Hara, Hai Nguyen, Yoshizumi Takechi, Bernd Gansbacher, Paul B. Chapman, Alan N. Houghton, Rejection of mouse melanoma elicited by local secretion of interleukin-2: implicating macrophages without T cells or natural killer cells in tumor rejection. International Journal of Cancer. ,vol. 61, pp. 253- 260 ,(1995) , 10.1002/IJC.2910610219
E. Janis, S. Kaufmann, R. Schwartz, D. Pardoll, Activation of gamma delta T cells in the primary immune response to Mycobacterium tuberculosis. Science. ,vol. 244, pp. 713- 716 ,(1989) , 10.1126/SCIENCE.2524098